2026³â 07¿ù 02ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb, the Company¡¯s novel transgenic chicken platform launchen 2023 that generates fully human and stabilized sdAbs
´º½ºÀÏÀÚ: 2024-06-11

EMERYVILLE, CALIF. -- OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.

sdAbs are produced naturally by camelids and have gained popularity as small, robust and highly modular building blocks for antibody discovery. While most other vertebrates use the standard heterodimeric IgG structure due to the pairing of heavy and light chains and do not produce sdAb format immunoglobulins, OmniAb’s scientific team led this study to investigate if chickens can support an immune repertoire based upon a heavy chain-only scaffold.

“Our team’s published data provided the foundational work supporting the feasibility of the Company’s next-generation transgenic chicken OmnidAb that produces fully human stabilized sdAbs. Unique physical properties of sdAbs can be leveraged for evolving fields of antibody discovery, including alternate routes of administration, diagnostic applications and therapeutic approaches that are being explored by many of our partners,” said Matt Foehr, Chief Executive Officer of OmniAb. “We currently have 80 partners leveraging OmniAb’s various platform technologies and accessing OmniAb antibodies, spanning major geographies and ranging from multinational big pharmas to venture-backed startups and leading academics.”

“Our truncated light chain chickens are designed to produce heavy (H) chain-only antibodies by deleting the light (L) chain variable region and maintaining only the constant region to serve as a chaperone for antibody secretion from the cell. We confirmed in this published study that the H chain variable region functions autonomously as a single domain without further engineering, producing sdAbs with favorable biophysical properties and antigen recognition profiles,” said Philip Leighton, Ph.D., Fellow of Molecular Biology of OmniAb. “Truncated L chain design successfully supported sdAb development and expression in chickens, and we are delighted that this work enabled the successful launch of OmnidAb.”



 Àüü´º½º¸ñ·ÏÀ¸·Î

SES Launches Multi-Orbit Satellite Connectivity on Mexico¡¯s Viva
Biocytogen Unveils AI-Powered RenSuper Platform and First Fully Automated Antibody Discovery System
Kwon Oh-tae from Donghae Aqua Unveils VINE7, a Seven-Day Vinegar Fermentation System
RevBits, Stony Brook Ethos Lab Partner to Advance Cybersecurity Education and Application
Silicon Motion Achieves ISO 26262 Certification for Automotive Applications
Poland¡¯s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education
ASC26 Student Supercomputer Challenge Concluded

 

2026 Esri User Conference to Focus on Creating a More Intelligent Worl...
HistoSonics Treats First Patients Using Edison Histotripsy System for ...
Parse Biosciences and bit.bio Announce Landmark Alliance
ExaGrid Wins 5 Industry Awards at Network Computing Awards 2026
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser...
Amazon, Netflix and Google to Capture Half of $81 Billion CTV Advertis...
Mevion Medical Systems Partners with Tam Anh General Hospital to Intro...

 


°øÁö»çÇ×
¹Ìµð¾î¿Í M• Mediaour ØÚ体ä² ØÚô÷ä² ¿¥¿À MO ØÚä²
¾Ë¸®¾Ë A⋮⋮⋮ Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
À£ÇÁ·Ò W⋮⋮⋮ Welfrom 卫ÜØ êÛÝ£
¹ÙÀÌ¿ÀÀÌ´Ï B⋮ BIOINI ù±药研 ¹ÙÀÌ¿ÀÀÌ´Ï·¦ BIOINILAB ...
º£³×ÀÍ ¡Õ Beneik 宝Ò¬ìÌ, À̺ñÁî eBizh æ¶币òª EZ æ¶òª
¿¡³ÊÀÌÀ¯ ¡Õ¡Õ EnerEU 额Òö äþÒö
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
¾Ë¸®À¯ºñ ^v Alliuv ä¹备 AV ä¹êó备, ¾Ë¶ã =^= Althle ä¹÷åìÌ
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º ¡ÕC À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¾ËÇÁ·Ò ^ Alfrom ä¹尔ÜØ ä¹ì³ÜØ, ¿ÃÇÁ·Ò A⋮⋮ Allfrom &...

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..